NO20055708L - Syntetisk gen som koder for humant karsinembryonalt antigen og anvendelser derav - Google Patents

Syntetisk gen som koder for humant karsinembryonalt antigen og anvendelser derav

Info

Publication number
NO20055708L
NO20055708L NO20055708A NO20055708A NO20055708L NO 20055708 L NO20055708 L NO 20055708L NO 20055708 A NO20055708 A NO 20055708A NO 20055708 A NO20055708 A NO 20055708A NO 20055708 L NO20055708 L NO 20055708L
Authority
NO
Norway
Prior art keywords
cea
gene encoding
embryonic antigen
encoding human
synthetic gene
Prior art date
Application number
NO20055708A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055708D0 (no
Inventor
Nicola La Monica
Armin Lahm
Carmela Mennuni
Rocco Savino
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Publication of NO20055708D0 publication Critical patent/NO20055708D0/no
Publication of NO20055708L publication Critical patent/NO20055708L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70Enkephalins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20055708A 2003-05-05 2005-12-02 Syntetisk gen som koder for humant karsinembryonalt antigen og anvendelser derav NO20055708L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46797103P 2003-05-05 2003-05-05
US54361204P 2004-02-11 2004-02-11
PCT/EP2004/004802 WO2004099247A2 (fr) 2003-05-05 2004-05-03 Gene synthetique codant pour l'antigene carcinoembryonnaire humain et son utilisation

Publications (2)

Publication Number Publication Date
NO20055708D0 NO20055708D0 (no) 2005-12-02
NO20055708L true NO20055708L (no) 2006-02-06

Family

ID=33436748

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055708A NO20055708L (no) 2003-05-05 2005-12-02 Syntetisk gen som koder for humant karsinembryonalt antigen og anvendelser derav

Country Status (12)

Country Link
US (1) US20070104685A1 (fr)
EP (1) EP1622937A2 (fr)
JP (1) JP2007523610A (fr)
KR (1) KR20060003903A (fr)
CN (1) CN1784424A (fr)
AU (1) AU2004235943A1 (fr)
CA (1) CA2523720A1 (fr)
IS (1) IS8053A (fr)
NO (1) NO20055708L (fr)
NZ (1) NZ543922A (fr)
RU (1) RU2005137697A (fr)
WO (1) WO2004099247A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1658370A1 (fr) * 2003-08-22 2006-05-24 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Gene de synthese codant pour un antigene carcino-embryonnaire de singe rhesus, et ses utilisations
EP1716173B8 (fr) * 2004-02-11 2012-06-27 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Proteines de fusion a antigene carcinoembryonique et utilisations de ces proteines
JP4881623B2 (ja) 2006-01-27 2012-02-22 シスメックス株式会社 Cea核酸増幅用プライマー、プライマーセット、及びがんの診断支援方法
WO2007090596A1 (fr) * 2006-02-06 2007-08-16 Medizinische Universität Wien Vaccin et mimotopes d'antigènes dirigés contre les maladies cancéreuses associées à l'antigène
EP3061462B1 (fr) 2007-07-02 2019-02-27 Etubics Corporation Procédés et compositions permettant de produire un vecteur d'adénovirus destiné à être utilisé avec des vaccinations multiples
US7994276B2 (en) * 2007-07-27 2011-08-09 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
WO2009117656A2 (fr) * 2008-03-21 2009-09-24 Vectorlogics,Inc. Antigène incorporé dans la capside pour nouveau vaccin à adénovirus
KR101815322B1 (ko) * 2010-01-12 2018-01-05 서울대학교산학협력단 항암 펩타이드 서열
US9605276B2 (en) * 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
JP6647315B2 (ja) 2015-01-09 2020-02-14 イーチュービクス コーポレイション 組み合わせ免疫療法のための方法および組成物
CN107530383A (zh) 2015-01-09 2018-01-02 埃图比克斯公司 用于埃博拉病毒疫苗接种的方法和组合物
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
US20210388383A1 (en) * 2018-10-12 2021-12-16 Children's Hospital Medical Center Modular expression systems for gene expression and methods of using same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795737A (en) * 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
DE10055545A1 (de) * 2000-11-09 2002-07-25 Deutsches Krebsforsch Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen

Also Published As

Publication number Publication date
NZ543922A (en) 2008-05-30
NO20055708D0 (no) 2005-12-02
RU2005137697A (ru) 2006-05-10
WO2004099247A3 (fr) 2005-02-24
CA2523720A1 (fr) 2004-11-18
US20070104685A1 (en) 2007-05-10
EP1622937A2 (fr) 2006-02-08
IS8053A (is) 2005-09-29
AU2004235943A1 (en) 2004-11-18
KR20060003903A (ko) 2006-01-11
WO2004099247A2 (fr) 2004-11-18
JP2007523610A (ja) 2007-08-23
CN1784424A (zh) 2006-06-07

Similar Documents

Publication Publication Date Title
NO20055708L (no) Syntetisk gen som koder for humant karsinembryonalt antigen og anvendelser derav
NO20060813L (no) Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav
EP1716173B8 (fr) Proteines de fusion a antigene carcinoembryonique et utilisations de ces proteines
ATE474048T1 (de) Her2/neu fusionsproteine
CY1121132T1 (el) ΠΛΗΡΩΣ-ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ANTI-vap-1
DE602004027902D1 (de) Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
IL198012A0 (en) Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
NZ746916A (en) Construction of oncolytic herpes simplex viruses (ohsv) obligate vector and constructs for cancer therapy
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
DE69839970D1 (de) Methoden zu herstellung von genbanken
Kim et al. Poxviral vectors for cancer immunotherapy
WO2002012341A3 (fr) Protéines de fusion her-2/neu
WO2002101075A9 (fr) Identification, evaluation, prevention et traitement du cancer du col de l'uterus : nouveaux genes, nouvelles compositions, nouvelles trousses et nouvelles methodes
RU2007136026A (ru) Варианты ил-21
WO2001074859A3 (fr) Gene exprime de maniere differentielle dans le cancer du sein et de la vessie et polypeptides codes
WO2011119925A3 (fr) Virus synthétiques de l'herpès simplex pour le traitement de cancers
MX2009003679A (es) Composicion de adn para provocar una respuesta inmune contra los macrofagos asociados a tumores.
EP1536006A4 (fr) Antigenes cancereux et leur utilisation
ES2329689T3 (es) Composiciones y procedimientos para el diagnostico de tumores.
Kang et al. Targeted coating with antigenic peptide renders tumor cells susceptible to CD8+ T cell-mediated killing
WO2003044161A3 (fr) Amplification et surexpression de gene dans le cancer
BR112021025943A2 (pt) Antígenos específicos de tumor inovadores para câncer de ovário e usos dos mesmos
Abedi et al. Impacts of the prostate stem cell antigen (PSCA) and Clostridium perfringens enterotoxin (CPE) on the apoptosis and cell cycle regulatory genes in PC3
ATE331796T1 (de) Rhesus-karzinoembryonales antigen, dieses codierende nukleotide und verwendungen davon
DE60226956D1 (de) Verstärktes krebs-gen wip1

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application